Marinus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Marinus Pharmaceuticals

05/03/2024 23:28

* Marinus Pharmaceuticals Inc  MRNS.OQ  reported a quarterly
adjusted loss of 74 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -76 cents.  The mean expectation of
eleven analysts for the quarter was for a loss of 62 cents per
share. Wall Street expected results to range from -69 cents
to -52 cents per share.
    * Revenue rose 0.4% to $7.19 million from a year ago;
analysts
expected $8.02 million. 
    * Marinus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 74 cents​.
    * The company reported a quarterly loss of $41.77 million.
    * Marinus Pharmaceuticals Inc shares had fallen by 12.2%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $21.00 

This summary was machine generated from LSEG data March 5 at
11:27 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.62          -0.74          Missed
 Sep. 30 2023      -0.66          -0.61          Beat
 Jun. 30 2023      -0.72          -0.61          Beat
 Mar. 31 2023      -0.72          -0.67          Beat